1. Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
   Stephanie J. Yaung et al, 2022, Cancers CrossRef
2. Correlation of Transrenal Dna with Non-Small-Cell Lung Cancer in Noninvasive Disease Monitoring
   Ziyang Zhu et al, 2021, Biomarkers in Medicine CrossRef
3. Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma
   Álvaro Taus et al, 2021, Archivos de Bronconeumología CrossRef
4. Prognostic value of pre-treatment red blood cell distribution width in lung cancer: a meta-analysis
   Yan Wang et al, 2020, Biomarkers CrossRef
5. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
   Sissel Gyrid Freim Wahl et al, 2021, The Journal of Pathology: Clinical Research CrossRef
6. A robust six-gene prognostic signature based on two prognostic subtypes constructed by chromatin regulators is correlated with immunological features and therapeutic response in lung adenocarcinoma
   Qiang Chen et al, 2023, Aging CrossRef
7. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
   Klara Cervena et al, 2019, Mutation Research/Reviews in Mutation Research CrossRef
8. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis
   Hongchang Shen et al, 2017, Oncotarget CrossRef
9. Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy
   Weiying Kong et al, 2023, Liquid Biopsies CrossRef
10. Development in the Diagnostic Lung Cancer Pathway: Implication for Treatment
    Cristina Migali et al, 2014, Lung Cancer Management CrossRef
11. Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age
    Akihiko Miyanaga et al, 2019, Biomarkers in Cancer Therapy CrossRef
12. Diagnostics and Therapy for Malignant Tumors
    Chung-Che Tsai et al, 2024, Biomedicines CrossRef
13. Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma
    Álvaro Taus et al, 2021, Archivos de Bronconeumología (English Edition) CrossRef
14. The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
    Xiaolong Zhao et al, 2021, Frontiers in Oncology CrossRef
15. Circulating Cell-Free Tumour DNA in the Management of Cancer
    Glenn Francis et al, 2015, International Journal of Molecular Sciences CrossRef
16. Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis
    Jiguang Jia et al, 2018, The International Journal of Biological Markers CrossRef
17. Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer
    Shanshan Ding et al, 2019, Thoracic Cancer CrossRef
18. An Investigation into Cell-Free DNA in Different Common Cancers
    Samira Nafar et al, 2024, Molecular Biotechnology CrossRef
19. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
    Simona Coco et al, 2017, International Journal of Molecular Sciences CrossRef
20. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis
    Rongyuan Zhuang et al, 2017, PLOS ONE CrossRef
21. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
    Ivana Bratić Hench et al, 2018, Frontiers in Medicine CrossRef
22. Develop Micro/Nano Technologies for Cancer Diagnosis
    Si-Yang Zheng, 2021, 2021 IEEE 34th International Conference on Micro Electro Mechanical Systems (MEMS) CrossRef
23. Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis
    Sarah Cargnin et al, 2017, Journal of Thoracic Oncology CrossRef
24. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
    L. Sorber et al, 2017, Lung Cancer CrossRef
25. Lung Cancer Staging and Prognosis
    Gavitt A. Woodard et al, 2016, Lung Cancer CrossRef
26. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
    Yang Yang et al, 2017, Oncotarget CrossRef
27. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
    Bo Ai et al, 2016, Oncotarget CrossRef
28. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
    Pieter A. Boonstra et al, 2020, Cancer and Metastasis Reviews CrossRef
29. Application of Circulating Cell‐free DNA for Personalized Cancer Therapy
    Indranil Chattopadhyay, 2020, Precision Medicine in Oncology CrossRef
30. The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
    Frederik van Delft et al, 2020, Cancers CrossRef
31. Liquid biopsy - emergence of a new era in personalized cancer care
    Jessy Abraham et al, 2018, Applied Cancer Research CrossRef